Note 10 - Segment Information

9 Months Ended

Jan. 31, 2018

Notes

Note 10 - Segment Information

NOTE 10 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three months ended January 31, 2018 and 2017; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2018 and 2017 is as follows:

	Three Months Ended January 31,		Nine Months Ended January 31,
	2018	2017	2018	2017
Revenues:
Chinese medicine - third party	$        675,927	$        859,933	$       2,099,147	$     2,240,055
Chinese medicine - related party	0	0	0	0
Total Chinese medicine	675,927	859,933	2,099,147	2,240,055
Stevioside - third party	4,058,336	3,421,023	11,135,229	8,413,018
Stevioside - related party	1,591,329	2,129,371	1,858,709	5,591,740
Total Stevioside	5,649,665	5,550,394	12,993,938	14,004,758
Total segment and consolidated revenues	$     6,325,592	$     6,410,327	$     15,093,085	$   16,244,813
Interest income (expense):
Chinese medicine	$                386	$                105	$                  742	$                178
Stevioside	(152,055)	(100,363)	(387,670)	(270,334)
Total segment and consolidated interest expense	$       (151,669)	$       (100,258)	$         (386,928)	$       (270,156)
Depreciation and amortization:
Chinese medicine	$           33,531	$           70,011	$          170,961	$        218,060
Stevioside	300,818	356,809	1,032,021	1,057,808
Total segment and consolidated depreciation and amortization	$        334,349	$        426,820	$       1,202,982	$     1,275,868
Loss before income taxes:
Chinese medicine	$           (6,964)	$         (38,147)	$         (521,873)	$       (188,043
Stevioside	(551,179)	(508,840)	(2,278,166)	(1,336,510
Corporate and other	(314,667)	(358,697)	(1,021,871)	(1,125,711
Total consolidated loss before income taxes	$       (872,810)	$       (905,684)	$     (3,821,910)	$    (2,650,264

	January 31, 2018	April 30, 2017
Segment tangible assets:
Chinese medicine	$       1,088,871	$     1,319,227
Stevioside	7,361,462	6,921,970
Corporate and other	0	0
Total consolidated assets	$       8,450,333	$     8,241,197